IDEXX Laboratories Inc. (IDXX) Q4 2025 (USD): EPS 3.08 (exp. 2.93), Revenue 1.09bln (exp. 1.07bln); revenue outlook for 2026 in the range of 4.63-4.72bln (exp. 4.66bln)

IDEXX Laboratories reported stronger-than-expected earnings for Q4 2025, with EPS and revenue both exceeding analyst estimates.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

South African Total New Vehicle Sales (Jan) 50.07K (Prev. 48.98K)

AT&T (T) has closed its transaction to acquire Lumen's (LUMN) Mass Markets fibre business for USD 5.75bln in an all-cash transaction

IDEXX Laboratories Inc. (IDXX) Q4 2025 (USD): EPS 3.08 (exp. 2.93), Revenue 1.09bln (exp. 1.07bln); revenue outlook for 2026 in the range of 4.63-4.72bln (exp. 4.66bln)

SpaceX may reportedly announce a merger deal with xAI as soon as this week, Bloomberg reports

White House meeting with crypto and bank executives on stablecoins to commence at 18:00GMT/13:00ET, CryptoAmerica's Terrett reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This positive performance, alongside a solid revenue outlook for 2026 that aligns closely with expectations, suggests robust operational strength, potentially bolstering investor confidence in the healthcare sector and possibly influencing sector peers and market sentiment.

Related headlines

The whole workspace, free to try.

Try it free